Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical Co. is feeling the ups and downs of drug making having announced U.S. FDA approval of the angiotensin II receptor blocker Edarbi days after announcing the withdrawal of its long-time anti-inflammatory drug Dasen from the Japanese market
You may also be interested in...
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market
Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market